Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
644 people get IPXL articles and Market Currents by email alert.
Get email alerts on IPXL »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
5 Biotechs With January FDA Decision Date CatalystsDavid Zanoni • Mon, Dec 17, 2012
-
-
-
-
Using Options To Benefit From The Binary Nature Of FDA DecisionsDavid Anber • Thu, Oct 18, 2012 -
Top Ranked Stocks To Buy This WeekTodd Campbell • Tue, Oct 9, 2012 -
-
-
-
-
Impax Laboratories Inc. Q2 2010 Earnings Call TranscriptTue, Aug 3, 2010
-
Impax Laboratories Inc. Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Business Wire (Jun 5, 2013)
-
Business Wire (Jun 3, 2013)
-
Business Wire (May 24, 2013)
-
Business Wire (May 20, 2013)
-
Business Wire (May 20, 2013)
-
Business Wire (May 10, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 3, 2013)
-
at MarketWatch.com (Mar 5, 2013)
-
at MarketWatch.com (Mar 5, 2013)
-
at MarketWatch.com (Mar 4, 2013)
-
Business Wire (Mar 4, 2013)
-
Business Wire (Mar 1, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 8, 2013)
IPXL vs. ETF Alternatives
Company Description
Currently, there's no company description for IPXL.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, June 17, 2:37 PM The Supreme Court's ruling regarding challenges to generic drug deals "is a significant victory for American consumers, American taxpayers, and free markets," the FTC says, noting that the ruling against "pay-for-delay agreements" makes it clear that these deals are subject to antitrust scrutiny. As MarketWatch notes however, stocks have pretty much shrugged it off with Actavis (ACT -1%) and AbbVie (ABBV -0.8%) down a bit, Teva (TEVA +0.3%) acting like nothing happened, and Impax (IPXL -0.7%) down only fractionally. Comment! [Healthcare]
- Tuesday, May 28, 5:30 PM S&P announces some changes to its indices, with Impax Laboratories (IPXL) replacing Cymer (CYMI) and Tangoe (TNGO) replacing Hot Topic (HOTT) in the S&P SmallCap 600 index after the close of trading on Friday, May 31. ASML Holding NV is acquiring Cymer, while Private equity firm Sycamore Partners is acquiring Hot Topic, with both deals expected to be completed soon. IPXL -2% AH. Comment! [Healthcare, Tech, Consumer]
- Tuesday, May 21, 6:12 PM Four companies ignoring their shareholders' votes, according to Theo Francis: Impax Labs (IPXL), where three directors were retained despite failing to reach 50% approval; Occidental Petro (OXY), which counted 55M non-voting shares as voting against a proposal; Hecla Mining (HL), which left open a say-on-pay vote for an extra month; and NYSE Euronext (NXY), which continues to thwart the right to call special shareholder meetings. 1 Comment [Energy, Healthcare, Financials]
- Friday, May 17, 11:23 AM Impax Laboratories (IPXL -1.2%) says its Generic Division, Global Pharmaceuticals, has begun shipping its generic drug Zomig, which is used for the treatment of migraines in adults, as part of a licensing and distribution agreement with AstraZeneca (AZN). Comment! [Healthcare, Global & FX]
- Friday, May 10, 3:36 PM Shares of Endo Health (ENDP -3.6%) trade lower following a brief halt after the FDA denies its petition to block generic versions of its Opana ER. ZGNX +2.1%, IPXL +8.4%. Comment! [Healthcare, On the Move]
- Wednesday, May 1, 4:15 PM Impax Labs (IPXL): Q1 EPS of $0.37 beats by $0.16. Revenue of $148.5M beats by $19.65M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, May 1, 12:10 AM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP Comment! [Earnings]
- Tuesday, April 30, 5:35 PM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP 2 Comments [Earnings]
- Monday, April 29, 10:30 AM GlaxoSmithKline (GSK +0.1%) breaks off its relationship with Impax Laboratories (IPXL -1.1%) regarding the experimental Parkinson's drug Rytary due to "delays in the anticipated regulatory approval and launch dates in the countries in which GSK has rights to commercialize the product." GSK was working to develop and market Rytary outside of the U.S. and Taiwan. IPXL shares have yet to fully recover from a steep decline in March stemming from FDA concerns about the testing and evaluation process for Rytary. (PR) 1 Comment [Healthcare]
-
Tuesday, March 5, 12:55 PM
Midday top 10 gainers: ACUR +59%. HIMX +37%. MTG +25%. CREE +15%. APP +15%. ZOLT +15%. ASNA +14%. SNTS +14%. PKOH +14%. DYAX +13%.
Midday top 10 losers: IPXL -25%. RNIN -23%. DRWI -19%. REGI -17%. TELOZ -17%. SHIP -14%. CSUN -10%. SDT -10%. JCP -10%. PSTR -9%. Comment! [On the Move] -
Tuesday, March 5, 9:10 AM
Premarket gainers: HIMX +21%. ASNA +13%. ACRX +12%. MTG +11%. SNTS +9%. CREE +6%.
Losers: IPXL -21%. RNIN -16%. Comment! [On the Move] - Monday, March 4, 6:30 PM Impax Laboratories (IPXL) gets hammered after FDA inspectors say they've found continuing problems at the company's Hayward, California manufacturing facility that may affect new and pending drug applications. Issues the agency found include problems related to the testing and evaluation processes for its Parkinson's drug candidate Rytary, as well as other products. Inspectors also said the company failed to identify the cause of broken tablets of its anti-inflammatory drug Carprofen. Shares -18.8% AH. 2 Comments [Healthcare, On the Move]
-
Monday, March 4, 5:39 PM
After-hours top gainers, as of 5:15 p.m.: ASNA +13%. SNTS +8%. CPWR +4%. NDZ +3%. MTG +3%.
After-hours top losers: IPXL -20%. JCP -6%. GMXR -6%. TVL -3%. NSU -3%. Comment! [On the Move] - Monday, February 25, 4:18 PM Impax Labs (IPXL): Q4 EPS of $0.30 beats by $0.11. Revenue of $141.1M (-11% Y/Y) beats by $14.07M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, February 25, 12:10 AM Notable earnings after Monday’s close: ADSK, CZR, HALO, HCN, IPXL, LGCY, MELI, MR, OAS, OKE, OKS, SGY, TWI, URS, VVUS Comment! [Earnings]
- Sunday, February 24, 5:35 PM Notable earnings after Monday’s close: ADSK, CZR, HALO, HCN, IPXL, LGCY, MELI, MR, OAS, OKE, OKS, SGY, TWI, URS, VVUS Comment! [Earnings]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.